James Gern, MD, was recently awarded $408,456 over 2 years from the National Institutes of Health-National Institute of Allergy and Infectious Diseases as a supplement to his current award, “Mechanisms of Rhinovirus-Induced Exacerbations of Asthma.” This project was funded under the American Recovery and Reinvestment Act (ARRA) of 2009 and will support a clinical trial to determine the best dose of a new human Rhinovirus type 16 inoculum manufactured using reverse genetics (RG-HRV16) for use in future experimental cold studies and to characterize the newly identified Rhinovirus type C and establish a tissue culture system to support RVC growth.